SRZNHIGH SIGNALFINANCIAL10-K

SRZN experienced a catastrophic financial deterioration with net losses nearly tripling to $242M, stockholders' equity plunging to negative $187.8M, and revenue collapsing 67% despite a significant cash infusion.

The company appears to be in severe financial distress with massive cash burn accelerating and fundamental business performance deteriorating rapidly. While they raised substantial capital (evidenced by the cash increase to $89.2M), the dramatic increase in total liabilities to $286.5M and deeply negative equity position suggest potential solvency concerns that investors should monitor closely.

Comparing 2026-03-23 vs 2025-03-31View on EDGAR →
FINANCIAL ANALYSIS

SRZN's financials show a company in crisis with net losses expanding 281% to $242M while revenue collapsed 67% to just $3.5M, indicating core business fundamentals are severely deteriorating. The company appears to have raised significant capital (cash increased 158% to $89.2M) but this was overwhelmed by a 310% surge in total liabilities to $286.5M, driving stockholders' equity to a deeply negative $187.8M. The overall picture signals potential solvency risk despite the recent capital raise, as operating cash flow losses widened 72% and the liability burden has grown dramatically.

FINANCIAL STATEMENT CHANGES
Stockholders Equity
Balance Sheet
-778.2%
-$21.4M-$187.8M

Equity declined sharply — large losses, buybacks, or write-downs reducing book value significantly.

Capital Expenditure
Cash Flow
+392.3%
$26K$128K

Capital expenditure jumped 392.3% — major investment cycle underway; assess returns on deployment.

Total Liabilities
Balance Sheet
+310.2%
$69.8M$286.5M

Liabilities grew 310.2% — significant increase in debt or obligations, assess impact on financial flexibility.

Net Income
P&L
-280.8%
-$63.6M-$242.0M

Net income declined 280.8% — review whether driven by operations, interest costs, or non-recurring items.

Cash & Equivalents
Balance Sheet
+158.2%
$34.6M$89.2M

Cash position surged 158.2% — strong cash generation or capital raise providing significant financial cushion.

Current Assets
Balance Sheet
+135.2%
$38.9M$91.6M

Current assets grew 135.2% — improving short-term liquidity or inventory/receivables build.

Total Assets
Balance Sheet
+103.7%
$48.5M$98.7M

Asset base grew 103.7% — expansion through organic growth, acquisitions, or capital deployment.

Operating Cash Flow
Cash Flow
-71.6%
-$17.6M-$30.2M

Operating cash flow fell 71.6% — earnings quality concerns; investigate working capital changes and non-cash items.

Revenue
P&L
-67.4%
$10.7M$3.5M

Revenue declined 67.4% — significant demand weakness or market share loss warrants investigation.

Operating Income
P&L
-64.8%
-$25.5M-$42.1M

Operating income deteriorated sharply — investigate whether driven by one-time charges or structural cost issues.

LANGUAGE CHANGES
NEW — 2026-03-23
PRIOR — 2025-03-31
ADDED
Overview We are a biotechnology company committed to discovering and developing product candidates to selectively modulate the Wnt pathway, a critical mediator of tissue repair.
Our current strategic focus is ophthalmology, where Wnt signaling plays a central role in retinal vascular integrity, barrier function, and tissue maintenance.
These breakthroughs enable us to rapidly and flexibly design tissue-targeted therapeutics that modulate Wnt signaling and form the foundation of our ophthalmology portfolio and research programs, which are designed to restore tissue structure and function in serious eye diseases with high unmet medical need.
Wnt signaling is essential in tissue maintenance and regeneration throughout the body.
Our current development efforts are focused on ophthalmology, where the biology of the Wnt pathway is clinically validated and localized delivery enables controlled therapeutic modulation.
+7 more — sign up free →
REMOVED
Overview We are a biotechnology company committed to discovering and developing drug candidates to selectively modulate the Wnt pathway, a critical mediator of tissue repair with a current focus in ophthalmology.
We are discovering and developing biologic drug candidates to selectively modulate the Wnt pathway, a critical mediator of tissue repair, in a broad range of organs and tissues, for human diseases.
These breakthroughs enable us to rapidly and flexibly design tissue-targeted therapeutics that modulate Wnt signaling.
As a result of our discoveries, we are pioneering the selective activation of Wnt signaling, designing and engineering Wnt pathway mimetics, and advancing tissue-selective Wnt candidates.
Given Wnt signaling is essential in tissue maintenance and regeneration throughout the body, we have the potential to target a wide variety of severe diseases, including certain diseases that afflict the intestine, liver, retina, cornea, lung, kidney, cochlea, skin, pancreas and central nervous system.
+7 more — sign up free →
MORE FINANCIAL SIGNALS
PNRGHIGHPNRG achieved exceptional profitability improvement with net income surging 2,21...
2026-04-16
BNAIHIGHBNAI underwent a dramatic reverse stock split that reduced share count by 86% wh...
2026-04-16
LAKEHIGHLAKE's financial performance deteriorated significantly with operating losses wo...
2026-04-16
NXXTHIGHNextNRG experienced massive financial deterioration with operating losses explod...
2026-04-16
ANALYZE ANY FILING FREE

See what changed in your portfolio's filings

500+ US-listed companies analyzed. Language delta, financial analysis, instant signal scoring.

Try Tracenotes free →